Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor

Inventiva is cutting approximately 50% of its workforce, primarily affecting its research team4.

The company is stopping all preclinical research activities except those supporting the lanifibranor program for metabolic dysfunction-associated steatohepatitis (MASH)4.

Inventiva is terminating work on its primary oncology program targeting the YAP-TEAD interaction in the Hippo signaling pathway4.

The restructuring is aimed at extending Inventiva's operational runway into the second half of 20264.

Over 95% of participants have been randomized in the Phase III NATiV3 trial for lanifibranor, with enrollment expected to complete in the first half of 20254.

Top-line results from the Phase III trial are anticipated in the second half of 20264.

Inventiva's 2024 revenue was 9.2 million euros ($9.5 million), down from 17.5 million euros ($18.1 million) in 20234.

The company expects to receive gross proceeds of about 116 million euros ($119.8 million) from structured financing and a milestone payment in Q2 20254.

Inventiva voluntarily paused patient recruitment for the NATiV3 trial in February 2024 due to a case of severe liver enzyme elevations4.

The restructuring plan is expected to be implemented in the second quarter of 20255.

Sources:

4. https://www.biospace.com/job-trends/inventiva-to-halve-its-workforce-shift-focus-to-mash-candidate

5. https://www.biospace.com/press-releases/inventiva-reports-preliminary-2024-fiscal-year-financial-results%C2%B9-and-provides-a-business-update